Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd raised its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 742.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 96,367 shares of the company’s stock after buying an additional 84,926 shares during the period. Y Intercept Hong Kong Ltd owned about 0.06% of Centessa Pharmaceuticals worth $3,828,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of CNTA. SG Americas Securities LLC increased its stake in shares of Centessa Pharmaceuticals by 1,017.7% in the 4th quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock valued at $6,593,000 after purchasing an additional 240,039 shares in the last quarter. Foresite Capital Management VI LLC boosted its position in Centessa Pharmaceuticals by 4.8% during the third quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock worth $31,865,000 after purchasing an additional 60,640 shares in the last quarter. Cinctive Capital Management LP purchased a new position in Centessa Pharmaceuticals during the third quarter worth approximately $2,246,000. Avoro Capital Advisors LLC grew its holdings in Centessa Pharmaceuticals by 116.2% in the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after purchasing an additional 5,808,080 shares during the period. Finally, Capital World Investors grew its holdings in Centessa Pharmaceuticals by 64.3% in the third quarter. Capital World Investors now owns 684,805 shares of the company’s stock valued at $16,607,000 after purchasing an additional 267,982 shares during the period. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA remained flat at $40.50 during trading on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $12.74 and a one year high of $40.56. The stock has a market capitalization of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11. The business has a 50-day simple moving average of $39.87 and a 200-day simple moving average of $32.22.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). As a group, equities analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on CNTA shares. Guggenheim downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Wells Fargo & Company lowered shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $35.00 to $42.00 in a report on Monday, April 20th. Wolfe Research cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Lifesci Capital downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Finally, Leerink Partners lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and lifted their target price for the company from $36.00 to $40.00 in a research report on Wednesday, April 1st. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.